BCRX
BioCryst Pharmaceuticals·NASDAQ
--
--(--)
--
--(--)
5.33 / 10
Netural
Analyst sentiment is mildly bullish with a unanimous Buy rating from one analyst, yet the historical win rate is only 40%, tempering conviction. Conversely, the fund-flow picture is encouraging, with a 7.79/10 score and positive trends across all size brackets, suggesting institutional accumulation that could provide a cushion against further declines.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
0%
Buy
100%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-30
InstitutionRBC Capital
Times predicted5
Historical Win Rate40.0%
What is the market sentiment for BCRX?
- BCRX holds a Bearish analyst rating, with 100% of experts assigning a Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 5.33/10 (Netural).
